(Q37605856)

21 August 2017

1 reference

title

Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels (English)

1 reference

21 August 2017

1 reference

1 reference

1 reference

Takashi Imamoto

1

1 reference

21 August 2017

Hiroyoshi Suzuki

2

1 reference

21 August 2017

Takanobu Utsumi

3

1 reference

21 August 2017

Takumi Endo

4

1 reference

21 August 2017

Makoto Takano

5

1 reference

21 August 2017

Masashi Yano

6

1 reference

21 August 2017

Koji Kawamura

7

1 reference

21 August 2017

Naoto Kamiya

8

1 reference

21 August 2017

Naoki Nihei

9

1 reference

21 August 2017

Yukio Naya

10

1 reference

21 August 2017

Tomohiko Ichikawa

11

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

7

1 reference

21 August 2017

page(s)

1005-1013

1 reference

What causes prostate cancer? A brief summary of the epidemiology

21 August 2017

cites work

1 reference

Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts

21 January 2018

1 reference

High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study

21 January 2018

1 reference

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

Testosterone and prostate cancer: an historical perspective on a modern myth

21 January 2018

1 reference

The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis

21 January 2018

1 reference

Hormones and prostate cancer: what's next?

21 January 2018

1 reference

STUDIES ON PROSTATIC CANCER

21 January 2018

1 reference

Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

21 January 2018

1 reference

Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review

21 January 2018

1 reference

Hormones and prostate cancer: current perspectives and future directions

21 January 2018

1 reference

Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy

21 January 2018

1 reference

Prospective study of sex hormone levels and risk of prostate cancer

21 January 2018

1 reference

Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis

21 January 2018

1 reference

The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.

21 January 2018

1 reference

The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening

21 January 2018

1 reference

Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer

21 January 2018

1 reference

Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.

21 January 2018

1 reference

External validation and head-to-head comparison of Japanese and Western prostate biopsy nomograms using Japanese data sets

21 January 2018

1 reference

5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males

21 January 2018

1 reference

Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth

21 January 2018

1 reference

Risks of testosterone-replacement therapy and recommendations for monitoring

21 January 2018

1 reference

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

21 January 2018

1 reference

Testosterone replacement therapy and the risk of prostate cancer: a perspective view

21 January 2018

1 reference

Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less

21 January 2018

1 reference

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

High-grade prostate cancer is associated with low serum testosterone levels

21 January 2018

1 reference

Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.

21 January 2018

1 reference

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy

21 January 2018

1 reference

Testosterone as a predictor of pathological stage in clinically localized prostate cancer

21 January 2018

1 reference

Association between prostate cancer and serum testosterone levels

21 January 2018

1 reference

Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer

21 January 2018

1 reference

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

21 January 2018

1 reference

Influence of radical prostatectomy on serum hormone levels

21 January 2018

1 reference

Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis

21 January 2018

1 reference

Circulating levels of inhibin, prolactin, TSH, LH, and FSH in benign prostatic hypertrophy before and after tumor resection

21 January 2018

1 reference

Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?

21 January 2018

1 reference

Elevated expression of inhibin alpha in prostate cancer.

21 January 2018

1 reference

Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer

21 January 2018

1 reference

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group

21 January 2018

1 reference

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

21 January 2018

1 reference

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy

21 January 2018

1 reference

Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome

21 January 2018

1 reference

The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer

21 January 2018

1 reference

Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.

21 January 2018

1 reference

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

21 January 2018

1 reference

The evolving role of oestrogens and their receptors in the development and progression of prostate cancer

21 January 2018

1 reference

Prevention of prostate cancer by androgens: experimental paradox or clinical reality

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.82

1 reference

21 August 2017

1 reference